INAB Insider Trading

Insider Ownership Percentage: 15.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

IN8bio Insider Trading History Chart

This chart shows the insider buying and selling history at IN8bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M$0$1MTotal Insider BuyingTotal Insider Selling

IN8bio Share Price & Price History

Current Price: $0.26
Price Change: Price Decrease of -0.0283 (-9.90%)
As of 01/22/2025 05:00 PM ET

This chart shows the closing price history over time for INAB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJan$0.26Closing price on 01/22/25:

IN8bio Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for IN8bio (NASDAQ:INAB)

92.05% of IN8bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at INAB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$65kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$1M-$500k$0$500k$1MTotal InflowsTotal Outflows
IN8bio logo
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Read More on IN8bio

Today's Range

Now: $0.26
Low: $0.26
High: $0.29

50 Day Range

MA: $0.30
Low: $0.23
High: $0.37

52 Week Range

Now: $0.26
Low: $0.22
High: $1.74

Volume

730,897 shs

Average Volume

962,011 shs

Market Capitalization

$18.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.04

Who are the company insiders with the largest holdings of IN8bio?

IN8bio's top insider shareholders include:
  1. William Tai-Wei Ho (CEO)
  2. Patrick Mccall (CFO)
  3. Jeremy R Graff (Director)
Learn More about top insider investors at IN8bio.